Page 8145
Mar 9, 2020
Eye-Opening Treatments — Medical Frontiers-JAPAN Live & Programs
Posted by Quinn Sena in categories: biotech/medical, life extension
3 minutes for glaucoma eye surgery.
Cataract and glaucoma are eye diseases that progress by aging. Both are severe diseases that can cause blindness, but in Japan, unique treatment methods and causes are being investigated. For cataracts, the world is paying attention to a Japanese doctor who has devised an innovative surgical method which is in just over 3 minutes. And distinctive research is progressing at Japanese universities as to what kind of ingredients can delay the progression of glaucoma. How can we save people from blindness? Explore with us the forefront of Japanese ophthalmic medical care.
:oooo.
A novel approach to treat glaucoma is reported that achieves reduced intraocular pressure by combining intravitreal adeno-associated virus (AAV) gene delivery to the ciliary body with selective CRISPR-Cas9-mediated disruption of Aquaporin 1. Translational viability is assessed using both human ex vivo ciliary body cultures and two experimental mouse models.
Mar 9, 2020
CRISPR enhancement, coronavirus source and a controversial appointment
Posted by Quinn Sena in category: biotech/medical
Mar 9, 2020
CRISPR Pill May Be Key in Fight Against Antibiotic Resistance
Posted by Quinn Sena in categories: biotech/medical, evolution
Even since Alexander Fleming stumbled across penicillin—the first antibiotic drug—scientists knew our fight with evolution was on.
Most antibiotics work by blocking biological processes that allow bacteria to thrive and multiply. With prolonged, low-dosage use, however, antibiotics become a source of pressure that forces bacteria to evolve—and because these microorganisms are extremely adept at swapping and sharing bits of their DNA, when one member becomes resistant, so does most of its population.
Continue reading “CRISPR Pill May Be Key in Fight Against Antibiotic Resistance” »
Mar 9, 2020
An experimental treatment for the new coronavirus is being tested in the US
Posted by Quinn Sena in categories: biotech/medical, health
The National Institutes of Health is testing the antiviral drug remdesivir, which is also being studied in patients in China. Running trials during epidemics is tricky, but scientists learned a lot about how to conduct them during recent Ebola outbreaks.
Mar 9, 2020
Researchers one step closer to creating organic batteries
Posted by Quinn Sena in category: materials
York University researchers have discovered a way to make Lithium-powered batteries more environmentally friendly while retaining performance, stability and storage capacity.
Lithium-ion batteries use toxic, heavy metals which can impact the environment when they are extracted from the ground and are difficult to dispose of safely. Cobalt is one of those heavy metals, used in battery electrodes. Part of the problem is that lithium and cobalt are not abundantly available, and supplies are dwindling.
Using organic materials are the way forward and that has scientists like Professor Thomas Baumgartner of the Faculty of Science and his team busy developing and testing new molecules to find the right ones to replace the rare metals currently in use.
Mar 9, 2020
Pet Safe provides an excellent protection shield for dogs, cats or other animals against NBC weapons using the same principal as a gas mask or protective enclosure
Posted by Quinn Sena in categories: government, military
Specializes in the sale of government and military-grade gas mask and protective clothing. Now offering Pet Safe : provides an excellent protection shield for dogs, cats or other animals against NBC weapons using the same principal as a gas mask or protective enclosure.
Mar 9, 2020
Antiviral activity of itraconazole against type I feline coronavirus infection
Posted by Quinn Sena in category: biotech/medical
Feline coronaviruses (FCoVs) are the causative agents of severe systemic disease (feline infectious peritonitis: FIP) in domestic and wild cats. FCoVs have been classified into serotypes I and II. Type I FCoV is the dominant serotype (approximately 70–90%) worldwide. Therefore, it is necessary to provide antiviral agents for type I FCoV infection. In this study, we demonstrated that itraconazole (ICZ), practically used for fungal infections in cats, inhibits the type I FCoV infection. ICZ also exhibited antiviral effect in cells after viral infection, suggesting that ICZ could potentially be used as a therapeutic.